Drugs / PolyPEPI1018
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05130060 | Jan 2022 → Jun 2023 | colon adenocarcinoma, metastatic malignant neoplasm in the colon, rectum adenocarcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03391232 | May 2018 → Jul 2019 | colorectal cancer | Treos Bio Zrt | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05243862 | Jun 2022 → Jul 2024 overdue | colorectal cancer | Treos Bio Limited | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PolyPEPI1018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03391232 ↗ |
| Modality | Vaccine | “PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from 7 tumor-associated antigens (TAA) frequently expressed in mCRC.” PMID 35472243 ↗ Jul 2022 |
| Route | Subcutaneous | “Eleven patients with MSS mCRC received PolyPEPI1018 and Montanide ISA51VG adjuvant subcutaneously” PMID 35472243 ↗ Jul 2022 |